Xeris debuts Gvoke HypoPen

Xeris Pharmaceuticals, a specialty pharmaceutical company, is introducing Gvoke HypoPen (glucagon injection) for the treatment of severe hypoglycemia in adults and children with diabetes ages 2 years and above.

Gvoke HypoPen is the first ready-to-use glucagon in a premixed autoinjector, with no visible needle, according to Xeris. It is available in two doses: 0.5 mg/0.1 mL for children (who weigh less than 100 pounds) and 1 mg/0.2 mL for adolescents and adults (who weigh 100 pounds or greater).

“We are excited to announce that Gvoke HypoPen is now available. The simplicity and reliability of Gvoke HypoPen has the potential to change people’s ability to confidently respond to a severe hypoglycemic event in a timely manner,” said Paul Edick, Xeris chairman and CEO. “In addition, as we prepared for launch, we had a heightened focus on ensuring Gvoke HypoPen is covered by insurance. Currently, approximately 78% of commercially insured and Medicare lives have unrestricted access to Gvoke HypoPen.”

"Gvoke HypoPen allows the diabetes community to change how we approach treating severe low blood sugar events," said Bruce Bode, of Atlanta Diabetes Associates. "Anyone can use Gvoke HypoPen in two simple steps. That opens the door for some patients to even give it to themselves, in certain situations. My hope is that what was once considered a crisis moment, can now become a manageable situation with Gvoke HypoPen."

For a limited time, eligible commercially insured patients may pay as little as $0 for a two-pack of Gvoke HypoPen by using the Gvoke copay savings card. Xeris also offers a Patient Assistance Program to help those who qualify to get Gvoke.